MedTrace Logo

Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy

NCT01777438 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 434

Last updated 2013-12-17

Study results available
· View outcomes & findings →

Summary

Allergic rhinitis (AR) is defined as inflammation of the nasal mucosa after exposition to an allergen in sensitized patients. AR causes not only nasal symptoms such as sneezing, itchy nose, rhinorrhea and nasal obstruction, but also has a significant impact on quality of life. Symptom control and overall satisfaction in patients undergoing subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) on the long term has not yet been investigated so far.

Conditions

  • Allergic Rhinitis

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Peter Hellings, MD · UZ Leuven

Eligibility

Min Age
19 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01777438 on ClinicalTrials.gov